Global Tuberculosis Drug Market 2017-2021 - Product Image

Global Tuberculosis Drug Market 2017-2021

  • ID: 4115405
  • Report
  • Region: Global
  • 76 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Archivel Farma
  • AstraZeneca
  • bioMérieux
  • Cepheid
  • EIKEN CHEMICAL
  • Epistem
  • MORE
About Tuberculosis Drug

Tuberculosis (TB) is caused by Mycobacterium tuberculosis and often affects the lungs. It spreads from person to person through the air in the form of a cough, sneeze or spit. TB affects adults more when compared with children.

The analysts forecast the global tuberculosis drug market to grow at a CAGR of 3.17% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global tuberculosis drug market for 2017-2021. To calculate the market size, the report considers the volume and services.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Tuberculosis Drug Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Lupin
- Otsuka Novel Products
- Pfizer
- Sandoz
- Sanofi

Other prominent vendors
- AstraZeneca
- Archivel Farma
- bioMérieux
- Cepheid
- EIKEN CHEMICAL
- Epistem

Market drivers
- Increase in outbreak of TB-HIV co-infections
- For a full, detailed list, view the full report

Market challenges
- Insufficient demand and high drug cost in developed countries
- For a full, detailed list, view the full report

Market trends
- Focus on development of shorter TB drug regimens
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Archivel Farma
  • AstraZeneca
  • bioMérieux
  • Cepheid
  • EIKEN CHEMICAL
  • Epistem
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: Key pipeline

PART 06: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 07: High burden countries (HBCs)

Categorization of HBCs

PART 08: TB diagnostics

Overview

PART 09: Market segmentation by disease type

Global latent TB market

Global active TB market

PART 10: Market segmentation by drug class

Global first-line anti-TB drugs market

Global second-line anti-TB drugs market

PART 11: Geographical segmentation

TB drugs market in Americas

TB drugs market in EMEA

TB drug market in APAC

PART 12: Market drivers

Increase in outbreak of TB-HIV co-infections

Emergence of MDR-TB and XDR-TB strains

Increasing incidence of TB in Africa and Asia

PART 13: Impact of drivers

PART 14: Market challenges

Insufficient demand and high drug cost in developed countries

Liberal regulations and lack of awareness in developing countries

Limited diagnostic procedures

PART 15: Impact of drivers and challenges

PART 16: Market trends

Increased spending on TB diagnostic kits

Focus on development of shorter TB drug regimens

Increased focus on TB vaccine development

PART 17: Vendor landscape

Competitive scenario

Key news

PART 18: Key vendor analysis

Lupin

Otsuka Novel Products

Pfizer

Sandoz

Sanofi

Other prominent vendors

PART 19: Appendix

List of abbreviations

PART 20: About the Author

List of Exhibits
Exhibit 01: Pipeline analysis
Exhibit 02: Key clinical trials
Exhibit 03: Global TB drugs market snapshot
Exhibit 04: Global TB drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global TB drugs market
Exhibit 06: Five forces analysis
Exhibit 07: List of major HBCs
Exhibit 08: Advanced technologies used for TB diagnostics
Exhibit 09: Tests recommended for diagnosis of active TB
Exhibit 10: Drugs used as first-line anti-TB agents
Exhibit 11: Global first-line anti-TB drugs market 2016-2021 ($ millions)
Exhibit 12: Drugs used as second-line anti-TB agents
Exhibit 13: Global second-line anti-TB drugs market 2016-2021 ($ millions)
Exhibit 14: TB drugs market scenario in Americas
Exhibit 15: TB drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Number of TB cases reported in US 2010-2015
Exhibit 17: TB drugs market scenario in EMEA
Exhibit 18: TB drugs market in EMEA 2016-2021 ($ millions)
Exhibit 19: TB drugs market scenario in APAC
Exhibit 20: TB drugs market in APAC 2016-2021 ($ millions)
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Testing process in BCG vaccines
Exhibit 24: Competitive structure analysis of global TB drug market 2016
Exhibit 25: Lupin: Key highlights
Exhibit 26: Lupin: Strength assessment
Exhibit 27: Lupin: Strategy assessment
Exhibit 28: Lupin: Opportunity assessment
Exhibit 29: Otsuka Novel Products: Key highlights
Exhibit 30: Otsuka Novel Products: Strength assessment
Exhibit 31: Otsuka Novel Products: Strategy assessment
Exhibit 32: Pfizer: Key highlights
Exhibit 33: Pfizer: Strength assessment
Exhibit 34: Pfizer: Strategy assessment
Exhibit 35: Pfizer: Opportunity assessment
Exhibit 36: Sandoz: Key highlights
Exhibit 37: Sandoz: Strength assessment
Exhibit 38: Sandoz: Strategy assessment
Exhibit 39: Sandoz: Opportunity assessment
Exhibit 40: Sanofi: Key highlights
Exhibit 41: Sanofi: Strength assessment
Exhibit 42: Sanofi: Strategy assessment
Exhibit 43: Sanofi: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Archivel Farma
  • AstraZeneca
  • bioMérieux
  • Cepheid
  • EIKEN CHEMICAL
  • Epistem
  • MORE
New Report Released: – Global Tuberculosis Drug Market 2017-2021

The author of the report recognizes the following companies as the key players in the global tuberculosis drug market: Lupin, Otsuka Novel Products, Pfizer, Sandoz, and Sanofi.

Other Prominent Vendors in the market are: AstraZeneca, Archivel Farma, bioMérieux, Cepheid, EIKEN CHEMICAL, and Epistem.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is focus on development of shorter TB drug regimens. MDR-TB needs a treatment course of second-line drugs over 18 months or more, which is quite higher than the standard six months of treatment with first-line TB drugs. Since last 5-7 years, the R&D efforts have been accelerated to reduce this elongated timeline and conventional treatment regimen for MDR-TB.”

According to the report, one of the major drivers for this market is increase in outbreak of TB-HIV co-infections. The risk of developing TB is 26-32 times greater in people living with HIV than among those without HIV. HIV and TB are inter-related co-infection where one could lead to another. It is very prominent to find individuals with HIV infection along with either latent or active TB disease.

Further, the report states that one of the major factors hindering the growth of this market is insufficient demand and high drug cost in developed countries. The potential of the market has reduced considerably because of the decline in the number of TB cases in developed countries. New TB cases are occurring only in developing countries. However, pharmaceutical companies presume that only a few individuals in developing countries can afford TB drugs. Moreover, the existing healthcare budgets and policies in developing countries are not quite attractive enough to lure the big pharmaceutical companies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Lupin
  • Otsuka Novel Products
  • Pfizer
  • Sandoz
  • Sanofi
  • AstraZeneca
  • Archivel Farma
  • bioMérieux
  • Cepheid
  • EIKEN CHEMICAL
  • Epistem
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll